Neurocrine Biosciences | NBIX - Себестоимость





Себестоимость Изменить Дата
AbbVie USD 4.29B 73M 2026-06
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
Agios Pharmaceuticals USD 1.32M 560K 2026-03
ALKERMES USD 120.7M 47.44M 2026-06
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Amgen USD 1.87B 271M 2026-06
Biogen USD 945.1M 147.6M 2026-06
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Cytokinetics USD 5.59M 5.43M 2026-06
Exelixis USD 20.66M 704K 2026-06
Gilead Sciences USD 1000M 445M 2026-06
Halozyme Therapeutics USD 108.68M 67K 2026-06
Incyte USD 104.96M 457K 2026-06
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Pfizer USD 4.09B 498M 2026-06
Prothena USD 28.94M 11.58M 2025-09
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Repligen USD 94.09M 8.12M 2026-06
Rigel Pharmaceuticals USD 8.03M 5.22M 2024-09
Sarepta Therapeutics USD 150.1M 40.64M 2026-06
Teva Pharmaceutical Industries USD 1.98B 30M 2026-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Vertex Pharmaceuticals USD 489.2M 96.4M 2026-06